REFERENCES
2. Peggs KS, Quezada SA. PD-1 blockade: promoting endogenous anti-tumor immunity. Expert Rev Anticancer Ther 2012;12:1279-82.
3. Velcheti V, Rimm DL, Schalper KA. Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1). J Thorac Oncol 2013;8:803-5.
4. Sznol M, Chen L. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res 2013;19:1021-34.
5. Hamid O, Carvajal RD. Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy. Expert Opin Biol Ther 2013;13:847-61.
6. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65.
7. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
8. Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov 2013;3:1355-63.
9. Davies M. New modalities of cancer treatment for NSCLC: focus on immunotherapy. Cancer Manag Res 2014;6:63-75.
10. Yang CY, Lin MW, Chang YL, Wu CT, Yang PC. Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. Eur J Cancer 2014;50:1361-9.
11. Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med 2015;21:24-33.
12. Pan ZK, Ye F, Wu X, An HX, Wu JX. Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis. J Thorac Dis 2015;7:462-70.
13. Karachaliou N, Cao MG, Teixidó C, Viteri S, Morales-Espinosa D, et al. Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints. Cancer Biol Med 2015;12:79-86.
14. Teixidó C, Karachaliou N, González-Cao M, Morales-Espinosa D, Rosell R. Assays for predicting and monitoring responses to lung cancer immunotherapy. Cancer Biol Med 2015;12:87-95.
15. Ochoa CE, Mirabolfathinejad SG, Ruiz VA, Evans SE, Gagea M, et al. Interleukin 6, but not T helper 2 cytokines, promotes lung carcinogenesis. Cancer Prev Res (Phila) 2011;4:51-64.
16. Hirsch FR, McElhinny A, Stanforth D, Ranger-Moore J, Jansson M, et al. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project. J Thorac Oncol 2017;12:208-22.
17. Lu J, Lee-Gabel L, Nadeau MC, Ferencz TM, Soefje SA. Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy. J Oncol Pharm Pract 2015;21:451-67.
18. O’Byrne K. Stimulating immune responses to fight cancer: basic biology and mechanisms. Asia Pac J Clin Oncol 2015;11:9-15.
19. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, et al. Nivolumab versus Docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015;373:123-35.
20. Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer 2019;19:133-50.
21. Pujol JL, De Pas T, Rittmeyer A, Vallières E, Kubisa B, et al. Safety and immunogenicity of the PRAME cancer immunotherapeutic in patients with resected non-small cell lung cancer: a phase I dose escalation study. J Thorac Oncol 2016;11:2208-17.
22. Tveita AA, Schjesvold F, Haabeth OA, Fauskanger M, Bogen B. Tumors escape CD4+ T-cell-mediated immunosurveillance by impairing the ability of infiltrating macrophages to indirectly present tumor antigens. Cancer Res 2015;75:3268-78.
23. Martin K, Schreiner J, Zippelius A. Modulation of APC function and anti-tumor immunity by anti-cancer drugs. Front Immunol 2015;6:501.
24. Scheel AH, Ansén S, Schultheis AM, Scheffler M, Fischer RN, et al. PD-L1 expression in non-small cell lung cancer: correlations with genetic alterations. Oncoimmunology 2016;5:e1131379.
25. Deeb KK, Hohman CM, Risch NF, Metzger DJ, Starostik P. Routine clinical mutation profiling of non-small cell lung cancer using next-generation sequencing. Arch Pathol Lab Med 2015;139:913-21.
26. Yang W, Lee KW, Srivastava RM, Kuo F, Krishna C, et al. Immunogenic neoantigens derived from gene fusions stimulate T cell responses. Nat Med 2019;25:767-75.
27. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015;348:124-8.
28. Saito K, Nakayama E, Valmori D, Kato T. Immune responses to the cancer testis antigen XAGE-1b in non small cell lung cancer caucasian patients. PLoS One 2016;11:e0150623.
29. Ohue Y, Kurose K, Nozawa R, Isobe M, Nishio Y, et al. Survival of lung adenocarcinoma patients predicted from expression of PD-L1, Galectin-9, and XAGE1 (GAGED2a) on tumor cells and tumor-infiltrating T cells. Cancer Immunol Res 2016;4:1049-60.
30. Yamamoto K, Venida A, Yano J, Biancur DE, Kakiuchi M, et al. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I. Nature 2020;581:100-5.
31. Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, et al. Tumor and microenvironment evolution during immunotherapy with Nivolumab. Cell 2017;171:934-49.e16.
32. Sarkizova S, Hacohen N. How T cells spot tumour cells. Nature 2017;551:444-6.
33. Balachandran VP, Łuksza M, Zhao JN, Makarov V, Moral JA, et al. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature 2017;551:512-6.
34. Łuksza M, Riaz N, Makarov V, Balachandran VP, Hellmann MD, et al. A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy. Nature 2017;551:517-20.
35. Pereira C, Gimenez-xavier P, Pros E, Pajares MJ, Moro M, et al. Genomic profiling of patient-derived xenografts for lung cancer identifies B2M inactivation impairing immunorecognition. Clin Cancer Res 2017;23:3203-13.
36. Bilsborough J, Panichelli C, Duffour MT, Warnier G, Lurquin C, et al. A MAGE-3 peptide presented by HLA-B44 is also recognized by cytolytic T lymphocytes on HLA-B18. Tissue Antigens 2002;60:16-24.
37. Chowell D, Morris LGT, Grigg CM, Weber JK, Samstein RM, et al. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science 2018;359:582-7.
38. Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature 2017;541:321-30.
39. Holtzhausen A, Zhao F, Evans KS, Tsutsui M, Orabona C, et al. Melanoma-derived Wnt5a promotes local dendritic-cell expression of IDO and immunotolerance: opportunities for pharmacologic enhancement of immunotherapy. Cancer Immunol Res 2015;3:1082-95.
40. Domagala-Kulawik J. The role of the immune system in non-small cell lung carcinoma and potential for therapeutic intervention. Transl Lung Cancer Res 2015;4:177-90.
41. Ager A, Watson HA, Wehenkel SC, Mohammed RN. Homing to solid cancers: a vascular checkpoint in adoptive cell therapy using CAR T-cells. Biochem Soc Trans 2016;44:377-85.
42. Mikucki ME, Fisher DT, Matsuzaki J, Skitzki JJ, Gaulin NB, et al. Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints. Nat Commun 2015;6:7458.
43. Slaney CY, Kershaw MH, Darcy PK. Trafficking of T cells into tumors. Cancer Res 2014;74:7168-74.
44. Pagès F, Galon J, Dieu-Nosjean MC, Tartour E, Sautès-Fridman C, et al. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 2010;29:1093-102.
45. Aithal A, Rauth S, Kshirsagar P, Shah A, Lakshmanan I, et al. MUC16 as a novel target for cancer therapy. Expert Opin Ther Targets 2018;22:675-86.
46. Gonzalez-Gugel E, Saxena M, Bhardwaj N. Modulation of innate immunity in the tumor microenvironment. Cancer Immunol Immunother 2016;65:1261-8.
47. He Y, Zhang X, Jia K, Dziadziuszko R, Zhao S, et al. OX40 and OX40L protein expression of tumor infiltrating lymphocytes in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers. Transl Lung Cancer Res 2019;8:352-66.
48. Messenheimer DJ, Jensen SM, Afentoulis ME, Wegmann KW, Feng Z, et al. Timing of PD-1 blockade is critical to effective combination immunotherapy with Anti-OX40. Clin Cancer Res 2017;23:6165-77.
49. Aspeslagh S, Postel-Vinay S, Rusakiewicz S, Soria JC, Zitvogel L, et al. Rationale for anti-OX40 cancer immunotherapy. Eur J Cancer 2016;52:50-66.
50. Webb GJ, Hirschfield GM, Lane PJ. OX40, OX40L and autoimmunity: a comprehensive review. Clin Rev Allergy Immunol 2016;50:312-32.
51. Ruffo E, Wu RC, Bruno TC, Workman CJ, Vignali DAA. Lymphocyte-activation gene 3 (LAG3): the next immune checkpoint receptor. Semin Immunol 2019;42:101305.
52. Puhr HC, Ilhan-Mutlu A. New emerging targets in cancer immunotherapy: the role of LAG3. ESMO Open 2019;4:e000482.
53. Andrews LP, Marciscano AE, Drake CG, Vignali DA. LAG3 (CD223) as a cancer immunotherapy target. Immunol Rev 2017;276:80-96.
54. Antonia SJ, Vansteenkiste JF, Moon E. Immunotherapy: beyond anti-PD-1 and anti-PD-L1 therapies. Am Soc Clin Oncol Educ Book 2016;35:e450-8.
56. Liu Q, Zhang C, Sun A, Zheng Y, Wang L, et al. Tumor-educated CD11bhighIalow regulatory dendritic cells suppress T cell response through arginase I. J Immunol 2009;182:6207-16.
57. Liu Y, Chen K, Wang C, Gong W, Yoshimura T, et al. Cell surface receptor FPR2 promotes antitumor host defense by limiting M2 polarization of macrophages. Cancer Res 2013;73:550-60.
58. Suzuki K, Sun R, Origuchi M, Kanehira M, Takahata T, et al. Mesenchymal stromal cells promote tumor growth through the enhancement of neovascularization. Mol Med 2011;17:579-87.
59. Yoshimura A. Signal transduction of inflammatory cytokines and tumor development. Cancer Sci 2006;97:439-47.
60. Wang YC, He F, Feng F, Liu XW, Dong GY, et al. Notch signaling determines the M1 versus M2 polarization of macrophages in antitumor immune responses. Cancer Res 2010;70:4840-9.
61. Wu H, Shang LQ, Chen RL, Yang SM, Wang SL, et al. Significance of Trask protein interactions in brain metastatic cohorts of lung cancers. Tumour Biol 2015;36:4181-7.
62. Huang WC, Chan ML, Chen MJ, Tsai TH, Chen YJ. Modulation of macrophage polarization and lung cancer cell stemness by MUC1 and development of a related small-molecule inhibitor pterostilbene. Oncotarget 2016;7:39363-75.
63. Zanin-Zhorov A, Flynn R, Waksal SD, Blazar BR. Isoform-specific targeting of ROCK proteins in immune cells. Small GTPases 2016;7:173-7.
64. Olsson A, Nakhlé J, Sundstedt A, Plas P, Bauchet AL, et al. Tasquinimod triggers an early change in the polarization of tumor associated macrophages in the tumor microenvironment. J Immunother Cancer 2015;3:53.
65. Wang Y, Sparwasser T, Figlin R, Kim HL. Foxp3+ T cells inhibit antitumor immune memory modulated by mTOR inhibition. Cancer Res 2014;74:2217-28.
66. Kim PS, Jochems C, Grenga I, Donahue RN, Tsang KY, et al. Pan-Bcl-2 inhibitor, GX15-070 (obatoclax), decreases human T regulatory lymphocytes while preserving effector T lymphocytes: a rationale for its use in combination immunotherapy. J Immunol 2014;192:2622-33.
67. Brcic L, Stanzer S, Krenbek D, Gruber-Moesenbacher U, Absenger G, et al. Immune cell landscape in therapy-naïve squamous cell and adenocarcinomas of the lung. Virchows Arch 2018;472:589-98.
68. Adah D, Hussain M, Qin L, Qin L, Zhang J, et al. Implications of MDSCs-targeting in lung cancer chemo-immunotherapeutics. Pharmacol Res 2016;110:25-34.
69. McDonald PC, Chafe SC, Dedhar S. Overcoming hypoxia-mediated tumor progression: combinatorial approaches targeting ph regulation, angiogenesis and immune dysfunction. Front Cell Dev Biol 2016;4:27.
70. Chafe SC, Lou Y, Sceneay J, Vallejo M, Hamilton MJ, et al. Carbonic anhydrase IX promotes myeloid-derived suppressor cell mobilization and establishment of a metastatic niche by stimulating G-CSF production. Cancer Res 2015;75:996-1008.
71. Orozco-Morales M, Soca-Chafre G, Barrios-Bernal P, Hernández-Pedro N, Arrieta O. Interplay between cellular and molecular inflammatory mediators in lung cancer. Mediators Inflamm 2016;2016:3494608.
72. Kargl J, Busch SE, Yang GH, Kim KH, Hanke ML, et al. Neutrophils dominate the immune cell composition in non-small cell lung cancer. Nat Commun 2017;8:14381.
73. Kargl J, Zhu X, Zhang H, Yang GHY, Friesen TJ, et al. Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC. JCI Insight 2019;4:130850.
74. Schlie K, Spowart JE, Hughson LR, Townsend KN, Lum JJ. When cells suffocate: autophagy in cancer and immune cells under low oxygen. Int J Cell Biol 2011;2011:470597.
75. Tittarelli A, Janji B, Van Moer K, Noman MZ, Chouaib S. The selective degradation of synaptic Connexin 43 protein by hypoxia-induced autophagy impairs natural killer cell-mediated tumor cell killing. J Biol Chem 2015;290:23670-9.
76. Rath M, Müller I, Kropf P, Closs EI, Munder M. Metabolism via arginase or nitric oxide synthase: two competing arginine pathways in macrophages. Front Immunol 2014;5:532.
77. Steggerda SM, Bennett MK, Chen J, Emberley E, Huang T, et al. Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment. J Immunother Cancer 2017;5:101.
78. Zhang Y, Fu J, Shi Y, Peng S, Cai Y, et al. A new cancer immunotherapy via simultaneous DC-mobilization and DC-targeted IDO gene silencing using an immune-stimulatory nanosystem. Int J Cancer 2018;143:2039-52.
79. Lemos H, Huang L, Prendergast GC, Mellor AL. Immune control by amino acid catabolism during tumorigenesis and therapy. Nat Rev Cancer 2019;19:162-75.
80. Mellor AL, Lemos H, Huang L. Indoleamine 2,3-Dioxygenase and tolerance: where are we now? Front Immunol 2017;8:1360.
81. Lemos H, Mohamed E, Huang L, Ou R, Pacholczyk G, et al. STING promotes the growth of tumors characterized by low antigenicity via IDO activation. Cancer Res 2016;76:2076-81.
82. Mondanelli G, Bianchi R, Pallotta MT, Orabona C, Albini E, et al. A relay pathway between arginine and tryptophan metabolism confers immunosuppressive properties on dendritic cells. Immunity 2017;46:233-44.
83. Timosenko E, Hadjinicolaou AV, Cerundolo V. Modulation of cancer-specific immune responses by amino acid degrading enzymes. Immunotherapy 2017;9:83-97.
84. Feng PH, Lee KY, Chang YL, Chan YF, Kuo LW, et al. CD14(+)S100A9(+) monocytic myeloid-derived suppressor cells and their clinical relevance in non-small cell lung cancer. Am J Respir Crit Care Med 2012;186:1025-36.
85. Raber P, Ochoa AC, Rodríguez PC. Metabolism of L-arginine by myeloid-derived suppressor cells in cancer: mechanisms of T cell suppression and therapeutic perspectives. Immunol Invest 2012;41:614-34.
86. Wang J, Matosevic S. Adenosinergic signaling as a target for natural killer cell immunotherapy. J Mol Med (Berl) 2018;96:903-13.
87. Ohta A. A metabolic immune checkpoint: adenosine in tumor microenvironment. Front Immunol 2016;7:109.
88. Vijayan D, Young A, Teng MWL, Smyth MJ. Targeting immunosuppressive adenosine in cancer. Nat Rev Cancer 2017;17:709-24.
89. Hay CM, Sult E, Huang Q, Mulgrew K, Fuhrmann SR, et al. Targeting CD73 in the tumor microenvironment with MEDI9447. Oncoimmunology 2016;5:e1208875.
90. Schmid S, Kübler M, Korcan Ayata C, Lazar Z, Haager B, et al. Altered purinergic signaling in the tumor associated immunologic microenvironment in metastasized non-small-cell lung cancer. Lung Cancer 2015;90:516-21.
91. Mittal D, Young A, Stannard K, Yong M, Teng MW, et al. Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor. Cancer Res 2014;74:3652-8.
92. Demaria O, Cornen S, Daëron M, Morel Y, Medzhitov R, et al. Harnessing innate immunity in cancer therapy. Nature 2019;574:45-56.
93. Mediavilla-Varela M, Luddy K, Noyes D, Khalil FK, Neuger AM, et al. Antagonism of adenosine A2A receptor expressed by lung adenocarcinoma tumor cells and cancer associated fibroblasts inhibits their growth. Cancer Biol Ther 2013;14:860-8.
94. Schumacher D, Strilic B, Sivaraj KK, Wettschureck N, Offermanns S. Platelet-derived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor. Cancer Cell 2013;24:130-7.
95. Gilbert SM, Oliphant CJ, Hassan S, Peille AL, Bronsert P, et al. ATP in the tumour microenvironment drives expression of nfP2X7, a key mediator of cancer cell survival. Oncogene 2019;38:194-208.
96. Takai E, Tsukimoto M, Harada H, Kojima S. Autocrine signaling via release of ATP and activation of P2X7 receptor influences motile activity of human lung cancer cells. Purinergic Signal 2014;10:487-97.
97. Takai E, Tsukimoto M, Harada H, Sawada K, Moriyama Y, et al. Autocrine regulation of TGF-β1-induced cell migration by exocytosis of ATP and activation of P2 receptors in human lung cancer cells. J Cell Sci 2012;125:5051-60.
98. Qian Y, Wang X, Liu Y, Li Y, Colvin RA, et al. Extracellular ATP is internalized by macropinocytosis and induces intracellular ATP increase and drug resistance in cancer cells. Cancer Lett 2014;351:242-51.
99. Qian Y, Wang X, Li Y, Cao Y, Chen X. Extracellular ATP a new player in cancer metabolism: NSCLC cells internalize ATP in vitro and in vivo using multiple endocytic mechanisms. Mol Cancer Res 2016;14:1087-96.
100. Germain C, Gnjatic S, Tamzalit F, Knockaert S, Remark R, et al. Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. Am J Respir Crit Care Med 2014;189:832-44.
101. Sautès-Fridman C, Petitprez F, Calderaro J, Fridman WH. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer 2019;19:307-25.
102. Sautès-Fridman C, Cherfils-Vicini J, Damotte D, Fisson S, Fridman WH, et al. Tumor microenvironment is multifaceted. Cancer Metastasis Rev 2011;30:13-25.
103. Draghiciu O, Lubbers J, Nijman HW, Daemen T. Myeloid derived suppressor cells-an overview of combat strategies to increase immunotherapy efficacy. Oncoimmunology 2015;4:e954829.
104. Newick K, O’Brien S, Moon E, Albelda SM. CAR T cell therapy for solid tumors. Annu Rev Med 2017;68:139-52.
105. Majzner RG, Mackall CL. Tumor antigen escape from CAR T-cell therapy. Cancer Discov 2018;8:1219-26.
106. Mollanoori H, Shahraki H, Rahmati Y, Teimourian S. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment. Hum Immunol 2018;79:876-82.
107. Li Y, Hermanson DL, Moriarity BS, Kaufman DS. Human iPSC-Derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity. Cell Stem Cell 2018;23:181-92.e5.
108. Mehta RS, Rezvani K. Chimeric antigen receptor expressing natural killer cells for the immunotherapy of cancer. Front Immunol 2018;9:283.
109. Rezvani K, Rouce R, Liu E, Shpall E. Engineering natural killer cells for cancer immunotherapy. Mol Ther 2017;25:1769-81.
110. Saetersmoen ML, Hammer Q, Valamehr B, Kaufman DS, Malmberg KJ. Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells. Semin Immunopathol 2019;41:59-68.
111. Barkal AA, Brewer RE, Markovic M, Kowarsky M, Barkal SA, et al. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature 2019;572:392-6.
112. Feng M, Jiang W, Kim BYS, Zhang CC, Fu YX, et al. Phagocytosis checkpoints as new targets for cancer immunotherapy. Nat Rev Cancer 2019;19:568-86.
113. Nigro A, Ricciardi L, Salvato I, Sabbatino F, Vitale M, et al. Enhanced expression of CD47 is associated with off-target resistance to tyrosine kinase inhibitor gefitinib in NSCLC. Front Immunol 2019;10:3135.
114. Stankovic B, Bjørhovde HAK, Skarshaug R, Aamodt H, Frafjord A, et al. Immune cell composition in human non-small cell lung cancer. Front Immunol 2018;9:3101.
115. Lee JM, Lee MH, Garon E, Goldman JW, Salehi-Rad R, et al. Phase I trial of intratumoral injection of CCL21 gene-modified dendritic cells in lung cancer elicits tumor-specific immune responses and CD8+ T-cell infiltration. Clin Cancer Res 2017;23:4556-68.
116. Saka H, Kitagawa C, Ichinose Y, Takenoyama M, Ibata H, et al. A randomized phase II study to assess the effect of adjuvant immunotherapy using α-GalCer-pulsed dendritic cells in the patients with completely resected stage II-IIIA non-small cell lung cancer: study protocol for a randomized controlled trial. Trials 2017;18:429.
117. Marinelli O, Nabissi M, Morelli MB, Torquati L, Amantini C, et al. ICOS-L as a potential therapeutic target for cancer immunotherapy. Curr Protein Pept Sci 2018;19:1107-13.
118. Popper H, Pongratz M. Value and indications for bronchoalveolar lavage combined with transbronchial lung biopsy. Wien Klin Wochenschr 1987;99:848-55.
119. Robinson PC, Watters LC, King TE, Mason RJ. Idiopathic pulmonary fibrosis. Abnormalities in bronchoalveolar lavage fluid phospholipids. Am Rev Respir Dis 1988;137:585-91.
120. Oshima M, Maeda A, Ishioka S, Hiyama K, Yamakido M. Expression of C-C chemokines in bronchoalveolar lavage cells from patients with granulomatous lung diseases. Lung 1999;177:229-40.
121. Magi B, Bini L, Perari MG, Fossi A, Sanchez JC, et al. Bronchoalveolar lavage fluid protein composition in patients with sarcoidosis and idiopathic pulmonary fibrosis: a two-dimensional electrophoretic study. Electrophoresis 2002;23:3434-44.
122. Bozinovski S, Jones JE, Vlahos R, Hamilton JA, Anderson GP. Granulocyte/macrophage-colony-stimulating factor (GM-CSF) regulates lung innate immunity to lipopolysaccharide through Akt/Erk activation of NFkappa B and AP-1 in vivo. J Biol Chem 2002;277:42808-14.
123. Yamauchi Y, Safi S, Blattner C, Rathinasamy A, Umansky L, et al. Circulating and tumor myeloid-derived suppressor cells in resectable non-small cell lung cancer. Am J Respir Crit Care Med 2018;198:777-87.
